Some cellular and molecular features of chronic lymphocytic leukaemia (CLL) cells that are associated with prognosis may reflect the context within which their progenitors encountered antigen. It follows that the nature of antigen drive in CLL could influence the clinical course and we were prompted to assess the impact, if any, of affinity maturation (an antigen-driven process) on prognosis. Statistical models for assessing affinity maturation status are typically applied to V H gene sequence data analysed using a web-based resource like IMGT or VBASE. Since these resources differ with respect to some key relevant features, we evaluated a cohort of CLL cases by applying statistical models to V H data derived from both IMGT and VBASE. Important differences between the resulting data sets became apparent. These resulted from database variance and because IMGT and VBASE define complementarity-determining and framework regions (CDRs, FRs) in different ways. Thus, the numbers of mutations identified and their distribution between CDRs/FRs varied between the data sets for the majority of clones. Consequently, two different but overlapping sets of cases with evidence of affinity maturation were defined. Notwithstanding their differences, no significant associations of affinity maturation status with CD38 expression, p53 functional status or survival were identifiable in either data set.
Introduction
Chronic lymphocytic leukaemia (CLL) is notoriously heterogeneous with respect to disease progression, response to therapy and outcome. 1, 2 This clinical diversity is reflected by a number of biological features. For example, differences in the functionality of the ATM-p53 pathway, the expression of CD38 and the mutational status of the immunoglobulin (Ig) V H gene utilised by the CLL clone can be used as indicators of prognosis. Thus, ATM-p53 dysfunction resulting from deletion and/or mutation of either gene 3 and CD38 expression on the surface of greater than 20-30% of the CLL cells in the clone [3] [4] [5] [6] are strongly associated with a short survival time, while extensive V H gene mutation is a good determinant of long survival time. 3, 5, 7, 8 During B-cell development, V H gene mutations are acquired by the antigen-initiated process of somatic hypermutation (SHM) and form the substrate for affinity maturation -the mechanism by which B cells with a progressively higher affinity for antigen are positively selected. 9 Since SHM and affinity maturation are classically thought of as being T-cell-dependent germinal centre (GC) reactions, cases of CLL with mutated V H genes have been considered to be clonal expansions of antigen-experienced, post-GC B cells and cases with unmutated V H genes to derive from naïve pre-GC B cells. 5, 7 However, this hypothesis is imperfect for several reasons; firstly, while it is unlikely that affinity maturation occurs independently of T cells, SHM can proceed outside GCs and, at least in murine models, without T cells. 10, 11 Secondly, not all cases of CLL with mutated V H genes have evidence of having undergone affinity maturation and therefore may not have been subjected to a normal GC reaction. 5, 12 Thirdly, gene expression profiling experiments have provided evidence that CLL cells, regardless of their V H gene mutational status, most closely resemble memory B cells. 13, 14 It has recently been shown that, while CLL cells have features of activated and antigen-experienced B cells independently of their V H gene status, differences in the expression of activation markers between unmutated and mutated CLL cases suggested that these groups differed with respect to the time or type of antigenic encounter they had experienced. 15 Studies of the BCR in CLL have reached similar conclusions. 16 These observations are consistent with the idea that CLL can evolve from B cells at different stages of differentiation or which have encountered antigen in different contexts and that this may influence survival.
SHM introduces mutations within recombined Ig V, (D) and J genes 9, 17, 18 and those that result in amino-acid changes (replacement (R) mutations) can alter affinity for antigen. Ig genes have evolved such that the complementarity-determining regions (CDRs; the regions largely responsible for direct antigen contact) are more susceptible to R mutations than the framework regions (FRs). 18, 19 Taking this into account, two statistical models have been proposed to determine the probability that a given mutated V H gene sequence has been selected by affinity maturation. The binomial distribution model described by Chang and Cassali 17 has more recently been extended by a multinomial distribution model described by Lossos et al. 20 Both models generate the probability that the number of mutations observed in the CDR and FR regions has occurred by chance. Thus, for the CDRs the probability that the observed number of R mutations significantly exceeds the number expected to occur randomly (ie in the absence of any selection) is evaluated as evidence of affinity maturation. For the FRs, the probability that the observed number of R mutations is significantly lower than the number expected to occur randomly is calculated and also provides evidence of affinity maturation. Opinions vary with regard to the relative merits of the binomial 17 and multinomial 20 models and, indeed, with regard to the validity of such approaches. [20] [21] [22] In practice, a good way of assessing the utility of predictive models is often to test them empirically by applying them to real biological data.
Immunoglobin sequence analyses are typically carried out using web-based resources. The international ImMunoGeneTics information System s IMGT 23 is a repository of immune system proteins of humans and other vertebrates maintained at the Université Montpellier. VBASE is a directory of human germline (GL) Ig genes compiled from Genbank and EMBL entries maintained by The Centre for Protein Engineering at the University of Cambridge. Both IMGT and VBASE provide tools facilitating pairwise comparisons between input sequences and database sequences. However, there are some differences between these two resources of particular significance to the type of investigation described here. Thus, the compositions of their Ig gene databases are overlapping but variant, they use different systems for annotating and numbering sequences and, most significantly, they employ different criteria for defining which amino acids comprise the CDRs/FRs of V H genes. In VBASE, alignments are annotated according to the structural criteria defined by Chothia [24] [25] [26] and the CDRs are defined by Kabat et al. 27 In IMGT, sequences are annotated and CDRs/FRs defined according to the IMGT unique numbering system. 28 Since investigators may use either IMGT or VBASE to help classify a V H sequence as GL (no somatic mutations, no affinity maturation), mutated and affinity matured (AM; evidence of having undergone affinity maturation) or mutated but nonaffinity matured (NAM), it is important to establish the nature of any differences that may arise from the two resources when identical sequences are examined.
AM status is a potential marker of differences in antigenic experience between CLL clones and there is much interest in the idea that antigen-driven selection may influence prognosis in CLL because it is widely believed to have a role, at some stage, in the pathogenesis of the disease. The aims of the work carried out here were, therefore to: (a) assess the nature of any differences that may arise from the use of IMGT vs VBASE with respect to the analysis of V H gene sequences, (b) compare the results of applying the binomial and multinomial models within and between IMGT and VBASE, (c) establish the nature of any relationships between the predicted affinity maturation status, p53 functional status, CD38 expression and extent of V H gene mutation in CLL and (d) determine whether or not the inferred affinity maturation status influences outcome in CLL.
Methods

CLL cases, V H gene sequences, p53 functional status, CD38 expression and statistical analyses
The patient cohort, V H gene sequence data, p53 functional status and CD38 expression were as described previously; 3, 29 the median age at diagnosis was 65 years, the male to female ratio was 1.65 and the distribution of clinical stages A, B and C was 42, 17 and 41%, respectively. Unless indicated otherwise, statistical calculations were carried out using SPSS (v. 10.7) or GNU R (v. 1.8.1).
Determination of V H gene mutational status and identification of GL V, D and J segments IMGT (http://imgt.cines. fr) and the VBASE (http://www.mrc-cpe/ cam.ac.uk) were searched (June 2003) with clonal V H gene sequences from the CLL cases to identify their most likely GL counterparts. Each resulting html file included sequence alignments to the five closest-matched GL V H , D H and J H segments, the positions of nucleotide differences between these and the input sequence and a translation of the CLL sequence showing the positions of the CDRs and FRs. Individual Perl (v. 5.6.1) scripts were written to extract information from these IMGT-and VBASE-derived html files. For an input CLL sequence, each Perl code first extracted and concatenated the CDR1 plus CDR2 and the FR1 plus FR2 plus FR3 sequences of the top-ranked GL V H sequence. The resulting contiguous CDR and FR sequences were then compared to the equivalent segments of the CLL sequence to identify nucleotide differences and to classify them as resulting in either replacement (R) or silent (S; no amino-acid change) mutations. When there was more than one nucleotide difference within a codon, it was assumed that they had occurred as separate, sequential events. The GL CDR and FR sequences were also used to calculate their replacement frequency (R f ) values (R fCDR and R fFR ) and their relative lengths (CDR rel and FR rel ). 17, 20 Perl code was used to identify RGYW (or the reverse complement, WRCY) motifs in GL sequences and to record instances where mutations occurred in these motifs.
Detection of affinity maturation
Both binomial 17 and multinomial 20 methods were used to test the null hypotheses that R mutations were not significantly in excess (or S mutations not scarce) in the CDRs, and that R mutations were not significantly scarce (or S mutations not in excess) in the FRs. Rejection of either or both null hypotheses was accepted as evidence that a CLL sequence had been selected by affinity maturation. Thus, sequences were classified as AM if Pp0.05 and NAM if P40.05.
In the binomial model, the probability of an R mutation (P(R)) in the CDRs was
Similarly, the probability of an R mutation in the FRs was
The probability of an S mutation was 1ÀP(R) in the respective region. The total number of mutations (R þ S) was n, so the probability distribution of R mutations in the CDRs was given by (P(R) CDR þ P(S) CDR ) n , while that for the FRs was given by (P(R) FR þ P(S) FR ) n . So, considering the CDR and FR separately, denoting P(R) as q, the probability of k R mutations was given by:
In the multinomial model, the parameters R mutation in the CDR, S in the CDR, R in the FR and S in the FR had observed frequencies of r 1 , s 1 , r 2 and s 2 and corresponding probabilities of p 1 , q 1 , p 2 and q 2 . Probabilities were calculated as:
The probability distribution of R mutations was given by (p 1 þ q 1 þ p 2 þ q 2 ) n . So, the probability of observing exactly k R mutations in the CDR region by chance was
The probability of observing exactly k R mutations in the FR region by chance was:
For both methods, the probability of observing at least K R mutations by chance was calculated using one-tailed tests: P(kpK) for the CDRs and P(kXK) for the FRs. The calculation of binomial probability was incorporated into the databasespecific Perl scripts, while multinomial probabilities were obtained using the resource at http://www-stat.stanford.edu/ immunoglobin. 20 
Results and discussion
We have considered any deviation of CLL V H gene sequences from their predicted GL sequences to be the result of somatic mutation for all of the following analyses. This avoids the use of an arbitrary cutoff percentage deviation from GL to distinguish between mutated (as opposed to polymorphic) and GL CLL V H sequences. This is justified by the recent observation that the majority of CLL V H gene sequences that differ from the predicted GL sequence by a small percentage are not due to polymorphisms 30 and is in accord with the conclusions drawn by Forconi et al.
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The inferred mutational status of clonal V H gene sequences from CLL patients differs between IMGT and VBASE data sets Sequences alignments were generated for 83 CLL cases using IMGT and VBASE (see Supplementary data).
In total, 11 CLL sequences were identified in both data sets as GL, while four were uniquely designated GL by IMGT and one was unique to VBASE. IMGT and VBASE identified 68 and 71 sequences, respectively, as deviating from those of the predicted GL V H gene. Of these, 67 were common to both data sets, one was unique to IMGT and four were unique to VBASE (Table 1) .
Of the 67 CLL clones classified as mutated in both data sets, 29 (43%) had a different number of mutations and 55 (82%) had a different distribution of R and S mutations between the CDRs and FRs, due to the differences in definition of CDRs/FRs. There were two reasons for the differences in the number of mutations identified. Firstly, in the majority (82%) of cases, the database accession with the highest-ranking match to the input sequence was different between IMGT and VBASE, despite the fact that they both use the same search algorithm. 32 While, in most cases, the same V H allele was identified in both data sets, in some instances the disparate accessions exhibited some sequence differences. Secondly, some of the differences between the input sequence and its predicted GL counterpart that occur towards the 3 0 end fall within codons classified as CDR3 by IMGT and FR3 by VBASE. Since CDR3 is not included in this type of study, these differences are not counted as mutations in the IMGT data set, but are included in VBASE.
Thus, due to the highlighted differences between IMGT and VBASE, the assigned mutational status (GL vs mutated and numbers of somatic mutations) of individual CLL V H sequences differed in a high proportion of cases. While these differences were usually marginal, they could have important consequences. For example, rigorously applying a percentage cutoff value for V H gene mutations to predict the outcome or to assign patients to one treatment group or another would have different consequences for some patients, depending on whether IMGT or VBASE were used.
The inference of affinity maturation status using the two statistical models gives similar but variant results and is influenced by the choice of immunogenetics resource used for analysis
The IMGT and VBASE alignment data sets (Supplementary data) were examined for evidence of affinity maturation using the binomial 17 and multinomial 20 statistical models. In agreement with previous reports, 5,7,12 a significant number of CLL clones with mutated V H genes showed no evidence of affinity maturation. While an explanation for the existence of such cases remains elusive, it seems plausible that they are selected by events (eg oncogenic mutations), occurring after the onset of SHM, that precede or preclude the completion of affinity maturation. The occurrence of mutations within RGYW motifs was significantly greater than would be expected by chance (Supplementary data). This is in accord with the observations of Messmer et al, 34 who suggest that this is evidence for the operation of a normal SHM mechanism in CLL cells with V H mutations. Table 2 records the numbers of cases where the CDR, FR or both CDR and FR were responsible for statistically significant evidence of AM. There was no significant difference in the numbers designated AM by either statistical method using IMGT-or VBASE-derived alignments. This suggests that there was no difference in efficiency of the detection of AM between the two statistical models. However, this observation should be interpreted with caution since the actual cases designated AM differed slightly between the datasets ( Figure 1 , Table 1 ). There was no significant difference between the number of cases where the CDRs, FRs or both CDRs and FRs were responsible for their classification as AM within the IMGT data set (Table 2) . However, the number of CDRs responsible for cases being designated as AM by both the binomial and multinomial models was significantly lower than the number of cases where either the FR or both the CDR and FR were responsible for AM classification in the VBASE data set ( Table 2 ). This suggests that, on the basis of mutations in the CDR only, a sequence is less likely to be classified as AM using VBASE-than using IMGTderived alignments, perhaps as a consequence of their different definitions of CDRs/FRs.
The multinomial model is argued to be more biologically realistic than the binomial approach. 20 In our series of patients the cases classified as AM by the binomial model were a subset of those classified AM by the multinomial model, regardless of whether IMGT or VBASE data sets were used ( Table 2 ). The multinomial model, therefore, seemed to be more inclusive, but we noted that the cases 'missed' by the binomial model but 'found' by the multinomial had probability scores close to 0.05 in both data sets (Supplementary data). The difference between the two methods is therefore quite marginal and we decided to use the data obtained by the multinomial method for all further analyses and discussion. Figure 2a and b shows the frequency distributions of the extent of somatic mutation for the AM and NAM groups in the two data sets. There were no significant differences between the AM groups or between the NAM groups of the IMGT and VBASE data sets. However, there were significant differences between the AM and NAM groups in both data sets. This analysis ( Figure  2a and b) therefore showed that the clones designated AM and NAM form distinct groups with respect to the frequency distribution of the extent of V H gene mutation, irrespective of whether data were derived from IMGT or VBASE. While this does not prove that the statistical model accurately defined the affinity maturation status of V H gene sequences, it clearly showed that it identified discrete groups of cases with mutated V H genes.
There was statistically significant evidence of AM in 47% (32/ 68) of the mutated CLL V H gene sequences using the IMGT data set and 42% (30/71) using the VBASE data set ( Table 1) . Of these, 24 were designated AM in both data sets, while 14 were unique to a single data set ( Figure 1 ). This discrepancy arises because, in some cases, the differences in the numbers of mutations and in their distribution between the CDRs and FRs, as defined by IMGT and VBASE, influenced the outcome of testing for evidence of affinity maturation. For example, CLL sequence 60L3a has 16 R and 8 S mutations when compared to its best-match GL counterpart, V3-15n01. According to the output from IMGT, there are eight R mutations and two S mutations in the CDRs and eight R mutations plus six S mutations in the FRs (Supplementary data), whereas according to VBASE there are six R and five S mutations in the CDRs and 10 R plus three S mutations in the FRs (Supplementary data). Consequently, the IMGT data result in this clone being designated AM, while the VBASE data result in the clone being classified as NAM. Thus, the application of the statistical model for the inference of affinity maturation status was strongly influenced by the choice of immunogenetics resource used. This is largely due to the differences in definition of CDRs/FRs, but also, to some extent, on the differences in database composition. Clearly, if affinity maturation were found to influence outcome in CLL, the use of IMGT vs VBASE would be an important consideration.
V H gene usage
The two data sets gave slightly different results with respect to frequency of individual gene usage (Supplementary data). The database annotations were sufficient for 77 comparisons to be made. There were no instances of a discrepancy between IMGT and VBASE with respect to the families of the GL V H genes identified for each CLL sequence. However, there were four instances where the allele identified differed between IMGT and VBASE: 48L3a (identified as V4-31 in IMGT and V4-34 in VBASE), 76L3a (identified as V3-76 in IMGT and V3-72 in VBASE), 40F1b and AS81 (both identified as V1-69 in IMGT and V1-e in VBASE). Furthermore, the actual accessions of the highest-ranking GL V H sequence identified for the same CLL sequence differed between the two databases in 68/83 (82%) of the cases.
The most frequently utilised V H genes according to both IMGT and VBASE data sets were V4-34 (nine in both IMGT and VBASE, five of which were designated AM in both databases), V3-21 (nine in IMGT, four of which were AM, and eight in The table records all of the cases designated AM for each dataset using both statistical methods and shows how many of these were assigned AM status by their CDRs alone, FRs alone and by both their CDRs and FRs. There was no significant difference in the number of cases designated AM by either method between IMGT-and VBASE-derived data (total numbers of AM cases in IMGT and VBASE compared to total numbers of cases designated AM by the binomial and multinomial models with Yates' correction applied, w
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[1] ¼ 0.0037, P ¼ 0.9512). Note that, since IMGT and VBASE employ different criteria for defining CDRs/FRs, an individual V H gene sequence can be classified as AM using the data derived from one resource but NAM by the other. 84% of the cases in the IMGT dataset and 77% in VBASE that were classified as AM by the multinomial method were also designated AM by the binomial method. a Expected value 46. w IMGT VBASE Figure 1 The overlap of CLL cases designated AM using IMGTand VBASE-derived sequence information. The figure illustrates the relationship between the cases classified as AM (by the multinomial model) using IMGT-and VBASE-derived sequence information. In all, 24 cases were classified as AM in both data sets, eight cases were unique to IMGT and six unique to VBASE. VBASE, three of which were AM) and V2-5 (six in IMGT, five of which were AM, and seven in VBASE, four of which were AM).
Since both immunogenetic resources employ the same search algorithm, the differences were presumably due to the differences in the precise designation of the GL sequence that was the best match to the CLL sequence. Such discrepancies do not, at present, have any consequences for the patient. However, since gene usage may reflect the nature of the antigen-driven element of CLL pathogenesis, these inconsistencies may affect our understanding of the development of the disease.
The relationship between AM/NAM status and extent of V H gene mutation Since affinity maturation involves successive rounds of somatic mutation and selection, it seemed likely that high levels of V H mutation would be associated with AM sequences. This is undoubtedly true in normal B cells, but in CLL progenitors the time at which oncogenic mutations occur may influence the selection of clones undergoing affinity maturation. We were therefore interested in determining the relationship between extent of V H mutation and the predicted AM/NAM status.
The graph in Figure 2c shows the number of clones that had diverged from GL by 40-5, 5-10 and 410%. Since, in all cases, the number of clones with 410% is much smaller than the numbers in the other two groups, it was only possible to conduct meaningful statistical tests by combining the 5-10 and 410% groups to form a 45% group. There was no statistical difference between the total number of CLL clones (ie combined NAM and AM groups) from the IMGT and VBASE data sets in the 0-5 and 45% groups (Table 3 ; Data set). When both IMGT and VBASE data sets were considered together and the AM and NAM groups compared, there was a significant difference in the number of clones in the 0-5% and 45% groups (Table 3 ; Status). Thus, the proportion of cases in the AM groups with higher levels of somatic mutations was significantly greater than that in the NAM groups. Nevertheless, a substantial number of cases within the NAM groups did have relatively high levels of Relationships between the extent of somatic mutation and AM/NAM status. The box plots show the frequency distributions of the extent of somatic mutations (%) of the AM and NAM groups for the (a) IMGT and (b) VBASE data sets. Each box represents 50% of the data, the median is indicated by the bar in each box and the extreme of the distribution (excluding outliers) is indicated by the whisker. The Mann-Whitney U-values based on a test of the difference between the AM and NAM distributions are indicated along with the probability scores for these tests. These show that in both data sets the AM and NAM distributions are significantly different. There was no significant difference in the median mutation % of the AM cases between the IMGT and VBASE data sets (U ¼ 459.5, P ¼ 0.773) or of the NAM cases between both data sets (U ¼ 726.5, P ¼ 0.906). The frequency distributions of the AM cases in both IMGT and VBASE data sets had similar symmetrical shapes with a range of 0.27-12.15% and a median value of ca. 6.5. Similarly, the frequency distributions of the NAM cases in both data sets were also comparable to each other, but differed significantly from the distribution in the AM clones. Although the range of % mutation (0.3-12.37%) in the NAM groups was similar to that in the AM groups, the frequency distribution was asymmetrical, being skewed to a median value of ca. 2.5 (mode ¼ 0.35 in both IMGT and VBASE data sets) with a long tail. The differences between the median levels of % mutation in the NAM and AM cases were statistically significant in both data sets. Therefore, the clones designated AM and NAM form distinct groups with respect to the frequency distribution of the extent of V H gene mutation, irrespective of whether data were derived from IMGT or VBASE. The bar chart (c) shows the proportions and numbers of cases whose V H sequence differed from the best-match GL sequence by 40-5, 5-10 and 410% for AM and NAM groups within each data set. The statistical analysis of the data is summarised in Table 3. mutation (Figure 2c, Table 3 ). In several of these examples (like 31L3a in IMGT and VBASE, and 11L4b and 56L3b in VBASE, all with 410% mutations; Supplementary data), there were high frequencies of R mutations within the FRs. This type of R mutation distribution explains why some CLL clones (designated NAM) have similar or greater levels of mutation than those found in AM sequences, with no evidence (according to the statistical models) of having been selected by affinity maturation. If the models are accurate, this suggests that extensively mutated cases that were classified as NAM were clonally selected by events or processes other than affinity maturation.
Cases of CLL classified as AM showed no association with p53 functional status or CD38 expression
Since both CD38 expression and p53 functional status are correlated with the extent of V H gene mutation and associated with prognosis in CLL, it was of interest to determine whether they had any relationship with AM/NAM status.
The relationship between the percentage of CD19 þ cells expressing surface CD38 and affinity maturation status in CLL cases with 40% V H gene mutation was assessed as shown in Supplementary data and Table 4 . The distribution of the percentages of CD38 þ cells in both AM-and NAM-designated cases in the IMGT and VBASE data sets was characteristically skewed, being clustered around a low modal value with a long tail. In the VBASE data, there were five outliers with high levels of CD38 þ cells in the AM group. There was no significant difference between the mean rank CD38% values of the AM groups from the IMGT or VBASE data sets. Similarly, there was no significant difference between the mean rank CD38% values in the NAM groups of either data set. When the NAM and AM groups were compared, there was no significant difference between the mean rank CD38% in the IMGT data set. However, there was a significant difference between the mean rank CD38% of the AM and NAM groups in the VBASE data set (Supplementary data). The latter outcome should be interpreted with some caution as the presence of the outliers with high levels of CD38 þ cells in the AM group may have unrealistically ranked the scores in the U-test. In fact, when the same results were analysed as counts-data using two alternative cutoff values (420 and 430% of CD19 þ cells expressing CD38) to define the proportions of CD38 þ cases, there was no significant association between numbers of cells expressing CD38 and affinity maturation status defined by the IMGT or VBASE data sets (Table 4) . CLL cases were categorised as p53 functional or dysfunctional according to their response to ionising radiation treatment. The Table 3 Relationships between extent of somatic mutation and AM/NAM status Within the IMGT data set 10 of the 36 (28%) NAM cases had more than 5% mutation and one (3%) had over 10%, while in the AM cases 19/32 (59%) had greater than 5% and 3/32 (9%) had greater than 10%. The VBASE data set had a similar picture, with 14/41 (32%) and 3/41 (7%) of the NAM cases having greater than 5 and 10% mutation, respectively, while in the AM group 21/41 (51%) and 4/41 (10%) had greater than 5 and 10% mutations, respectively (see also Figure 2c ). To carryout meaningful analyses, the 5-10 and 410% groups were combined. The statistics indicate that the AM groups (within and between datasets) have significantly more mutations than the NAM groups.
Table 4
Relationship between AM/NAM status and CLL cases expressing CD38 on 420% and 430% of cells For each data set, the table shows the numbers of AM and NAM cases expressing CD38 on greater than 420% or 430% of CD19+ cells. As indicated, there were no statistically significant differences between the AM and NAM groups with respect to CD38 expression at either percentage cutoff.
p53 dysfunctional cases were subcategorised as having either type A (associated with TP53 gene mutation) or type B (associated with ATM mutation) dysfunction as described previously. 3, 33 The relationship between p53 functional status and affinity maturation status was assessed as shown in Table 5 . There was no statistically significant difference between the numbers of p53 dysfunctional cases in the AM or NAM groups defined by either the IMGT or VBASE data sets. Additionally, there was no association between type A or type B p53 dysfunction and affinity maturation status in either data set.
Affinity maturation status predicted from V H gene sequence data is not associated with outcome in CLL Since the extent of SHM may be influenced by encounter with antigen and because limited SHM is associated with a poor outcome, 3, 8 it was of interest to determine if AM/NAM status similarly influences progression in CLL.
The relationships between survival (both disease-specific and overall survival) and affinity maturation status were examined for both the IMGT and VBASE data sets. Initially however, we assessed survival duration with respect to the degree of V H gene mutation to confirm the relationship we previously reported between these parameters using VBASE-derived data. 3, 29 The cases were compared in three V H -defined subgroups for each data set: 0-2, 2-5 and 45% sequence deviation from GL. The group with 45% V H gene mutations, defined by both IMGT and VBASE, had significantly longer overall (IMGT, P ¼ 0.0002; VBASE, P ¼ 0.0144; n ¼ 83 in both cases; data not shown) and disease-specific (IMGT, P ¼ 0.002; VBASE, P ¼ 0.0037; n ¼ 67; data not shown) median survival times than the median survival times of patients in the 0-2 and 2-5% groups.
The influence of affinity maturation status on survival was then examined with the same patient cohort. Three groups were defined in both the IMGT and VBASE data sets: patients with (1) GL V H genes, (2) mutated (40% sequence deviation from GL) V H genes that were designated NAM and (3) mutated V H genes that were designated AM. Kaplan-Meier plots of the diseasespecific and overall survival of these groups are shown in Figure 3 . There were no significant differences between the median overall or median disease-specific survival of the GL, NAM and AM groups in either data set (Figure 3 ). This indicates that the affinity maturation status, as defined by the multinomial model 20 of V H gene mutation, has no influence on the survival of patients with CLL. This is in marked contrast to the prognostic impact of V H mutation and its association with other adverse prognostic factors previously observed within the same cohort of patients. 3, 29 Patients with 45% V H mutation had significantly longer median survival times than patients with o5% V H mutation. Since 31% of AM clones and 72% of NAM clones had o5% V H mutation, the AM and NAM cases are mixed in terms of extent of V H mutation. Thus, this obscures the effect of extent of V H mutation on survival times when considering the AM/NAM status.
In agreement with our data, Krober et al 35 have also reported that antigen selection had no significant effect on survival time. In another recent report, Degan et al 36 defined three subgroups of CLL as unmutated (up to 2% V H gene sequence deviation from GL), significantly mutated (sM; 42% mutation with evidence of AM) and not significantly mutated (nsM; 42% mutations, no evidence of AM). In contrast to our own conclusion and that of Krober et al, 35 their data indicate that, among the mutated patients with a favourable prognosis (defined as those with more than 2% mutations), the sM group had a longer survival. The apparent discrepancy with our result might be explained by their use of the 2% cutoff value as this may skew the analysis for two reasons. Firstly, while there were no examples in the Degan et al 36 patient cohort, there are examples of cases with few mutations (o2%) and evidence of having undergone affinity maturation in our own patient series (Supplementary data) and that of Messmer et al. 34 This indicates that when considering the impact of AM status on survival, all cases with non-GL V H genes should be included. Secondly, although opinion varies, 37 our data (see above and Lin et al 3, 29 ) and another study 38 have indicated that 5 and 3% are more reliable cutoff values than 2% for defining a favourable prognosis on the strength of V H mutation.
Interpretation and conclusions
This work draws attention to some differences that arise as a consequence of choosing a particular immunogenetics resource for V H gene analyses. In a clinical setting, these differences may have important consequences. Thus, the work highlights the importance of combining different markers of prognosis in CLL. Some of our data could be used to make the case that the inference of affinity maturation status using the currently available sequence-based statistical methods is flawed. The immunogenetics resources used in this study differ in ways that affect the outcome of the application of these methods, as described above. Indeed, our two data sets categorised two overlapping but different sets of AM patients. Nevertheless, with respect to the correlations of AM/NAM status with other parameters, we obtained similar results from both data sets. Since the premise on which the models are based is dependent on the relative distribution of R mutations between the CDRs and FRs, it could be argued that we would not expect the two data sets to produce the same results, unless both definitions of CDRs/FRs are inaccurate. It has been shown experimentally that R mutations within the FRs can improve affinity for certain antigens. 39 If this were a more universal phenomenon than previously believed, it would also argue that the statistical models are invalid. It would also suggest that cases of CLL that have extensively mutated V H genes and exhibit relatively high numbers of R mutations in their FRs might have undergone affinity maturation, despite not being detected by the statistical models.
The precise delineation of the amino acids of specific Igs responsible for binding antigen is best established from structural studies. Since the IMGT and VBASE definitions of CDRs/FRs are extrapolated to varying degrees on such data, it is very likely that the two definitions actually reflect a consensus of the true biological situation. The two overlapping groups of AM patients described by our two data sets are thus skewed towards an accurately identified AM group, assuming that the hypothesis on which the statistical models are based is valid. These models are also extrapolated from data showing that the CDRs are primarily responsible for binding antigen. While it has been shown that R mutations in the FRs can increase affinity for antigen, 39 it is likely that excessive numbers would disrupt the functionality of the Ig. Therefore, the multinomial distribution model is likely to have a significant degree of accuracy without being absolutely precise.
In conclusion, we surmise that our combined (IMGT-and VBASE-derived) data are an indicator of the true biological situation. Our results therefore signify that the prognostic effect of V H gene mutation is independent of the context in which CLL clones with mutated V H genes encounter antigen. Furthermore, they suggest that, at least with respect to mutated CLL, the influence on outcome of events other than affinity maturation is greater than the influence of antigen-driven selection. Kaplan-Meier plots of overall and disease-specific survival according to AM, NAM and GL status. (a) Overall survival curves and (b) disease-specific survival curves of CLL patients classified as having GL, mutated-AM and mutated-NAM V H genes for both IMGT-and VBASEderived data. Disease-specific survival was obtained by censoring those deaths that could not be explained by CLL or its treatment. The P-values (probability that the median survival times in the three groups are different) indicate that there was no significant difference in duration of survival between these groups.
